Business Context and Reporting Period
Company: Daré Bioscience, Inc. (DARE)
Filing Type: Form 8-K (Current Report)
Date: October 17, 2022
Context: The filing discloses the topline results of a Phase 1/2 clinical study for DARE-HRT1, an investigational combination bio-identical 17β-estradiol and bio-identical progesterone intravaginal ring (IVR) designed to treat menopausal symptoms.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The primary material event is the announcement of positive topline results from a randomized, open-label, two-arm, parallel group Phase 1/2 study involving approximately 20 healthy, post-menopausal women.
- Efficacy: Both lower (80 µg estradiol/4 mg progesterone) and higher (160 µg estradiol/8 mg progesterone) dose formulations achieved statistically significant improvements (p<0.01) in vasomotor symptoms (VMS), genitourinary symptoms, vaginal pH, and maturation index.
- Quality of Life: Participants showed significant improvement across all domains of The Menopausal Quality of Life Survey (MENQOL), including physical, psychosocial, and sexual symptoms.
- Specific Symptoms: Vaginal dryness (reported by 70% at baseline) and vaginal pain showed significant improvement in both dose groups.
- Safety and Tolerability: The treatment was well tolerated with adverse events consistent with other vaginal products. There were two early discontinuations due to adverse events and no serious adverse events reported.
- Acceptability: 100% of subjects reported the IVR was comfortable to wear, with no expulsions reported. Over 95% stated they would likely use the device for future conditions.
Guidance, Outlook, and Risks
Outlook: Daré anticipates that topline pharmacokinetic (PK) data from the Phase 1/2 study will be available and reported later in the fourth quarter of 2022.
Management Commentary: The company views these results as supportive of DARE-HRT1's potential as a safe and effective hormone therapy and a potential first FDA-approved monthly IVR delivering both estrogen and progestogen.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include:
- Early clinical findings may not predict success in subsequent studies.
- Dependence on third parties for manufacturing and clinical trial conduct.
- Ability to raise additional capital to continue as a going concern.
- Regulatory approval uncertainties and patent litigation risks.
Investor Verification Checklist
- Verify the release of topline PK data in Q4 2022 as anticipated.
- Monitor the company's cash runway and capital raising activities given the lack of revenue and dependence on funding.
- Review the full clinical study data once published to assess the magnitude of efficacy and safety profile.
- Track regulatory interactions regarding the approval pathway for DARE-HRT1.